MOLECULAR PATHOLOGY OF PNEUMOCYSTIS PNEUMONIA
肺孢子虫肺炎的分子病理学
基本信息
- 批准号:6615811
- 负责人:
- 金额:$ 25.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-09-30 至 2005-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION: Alveolar macrophages from Pneumocystis carinii-infected hosts are
defective in phagocytosis, and the expression of the transcription factor
GATA-2 in these cells is severely down-regulated. Introduction of a
GATA-2-specific antisense oligonuceotide into alveolar macrophages from normal
uninfected animals also resulted in a decrease in the phagocytic activity of
these cells. In this proposed study, experiments will be performed to further
investigate the role of GATA-2 in alveolar macrophage phagocytosis. A GATA-2
expression vector will be introduced into alveolar macrophages from P.
carinii-infected hosts to investigate whether GATA-2 over-expression could
correct the defect. To further understand the involvement of GATA-2 in P.
carinii pathogenesis, genes that are regulated by GATA-2 in monocytes will be
identified. DNA microarrays will be probed with labeled cDNA from wild type and
GATA-2 knockout monocytes. The hybridized microarrays will then be analyzed to
determine which genes are regulated by GATA-2. Experiments will also be
performed to determine whether genes such as those encoding MMR, MIP-1alpha,
MCP-1, IL6 and TNF-alpha that are associated with functions of alveolar
macrophages are regulated by GATA-2. The mechanisms by which P. carinii causes
down regulation of GATA-2 in alveolar macrophages will be explored. Normal
alveolar macrophages will be incubated directly or indirectly with live or dead
P. carinii organisms to determine whether a P. carinii protein is responsible
for down regulation of GATA-2 transcription leading to a reduction in the
phagocytic activity of alveolar macrophages. Proteins such as vitronectin,
fibronectin, surfactant proteins A and D, and P. carinii major surface
glycoprotein, which are known to interact with alveolar macrophages during P.
carinii infection, will also be examined. These proteins will be incubated
either alone or in combination with normal macrophages to determine whether
they have any effect on GATA-2 down regulation. Different fractions of
bronchoalveolar lavage fluids from P. carinii-infected lung will also be
tested. Any P. carinii or host protein that is found to have the ability to
down regulate GATA-2 expression will be identified by sequencing a portion of
the protein.
描述:来自卡氏肺孢子虫感染宿主的肺泡巨噬细胞,
吞噬功能缺陷和转录因子的表达
这些细胞中的加塔-2被严重下调。引入
加塔-2特异性反义寡核苷酸进入正常人肺泡巨噬细胞
未感染的动物也导致了
这些细胞。在这项拟议的研究中,将进行实验,以进一步
探讨加塔-2在肺泡巨噬细胞吞噬中的作用。A加塔-2
将表达载体导入来自P.
卡氏虫感染宿主,以研究加塔-2过表达是否可以
纠正缺陷。为了进一步了解加塔-2在P.
在卡氏病发病机制中,单核细胞中受加塔-2调节的基因将被
鉴定DNA微阵列将用来自野生型和
加塔-2敲除单核细胞。然后分析杂交的微阵列,
确定哪些基因受加塔-2调控。实验也将
以确定是否存在编码MMR,MIP-1 α,
MCP-1、IL-6和TNF-α与肺泡上皮细胞功能相关
巨噬细胞受加塔-2调节。卡氏肺孢子虫引起
将探索肺泡巨噬细胞中加塔-2的下调。正常
肺泡巨噬细胞将直接或间接与活的或死的
卡氏肺孢子虫生物体,以确定卡氏肺孢子虫蛋白是否负责
用于下调加塔-2转录,从而导致细胞凋亡减少。
肺泡巨噬细胞的吞噬活性。蛋白质如玻连蛋白,
纤连蛋白、表面活性蛋白A和D以及卡氏肺孢子虫主表面
糖蛋白,这是已知的相互作用与肺泡巨噬细胞在P。
卡氏杆菌感染,亦会接受检查。这些蛋白质将被孵化
单独或与正常巨噬细胞组合,以确定是否
它们对加塔-2下调有任何影响。不同级分
来自卡氏肺孢子虫感染的肺的支气管肺泡灌洗液也将被
测试.任何卡氏肺孢子虫或宿主蛋白被发现具有以下能力:
下调加塔-2表达将通过对一部分
蛋白质。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHAO-HUNG LEE其他文献
CHAO-HUNG LEE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHAO-HUNG LEE', 18)}}的其他基金
Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia
维生素 D 作为肺孢子菌肺炎的补充疗法
- 批准号:
9063354 - 财政年份:2016
- 资助金额:
$ 25.55万 - 项目类别:
Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia
维生素 D 作为肺孢子虫肺炎的补充疗法
- 批准号:
9238656 - 财政年份:2016
- 资助金额:
$ 25.55万 - 项目类别:
相似海外基金
Prevention and Treatment of Pneumocystis Pneumonia
肺孢子虫肺炎的防治
- 批准号:
10605177 - 财政年份:2020
- 资助金额:
$ 25.55万 - 项目类别:
Prevention and Treatment of Pneumocystis Pneumonia
肺孢子虫肺炎的防治
- 批准号:
10382422 - 财政年份:2020
- 资助金额:
$ 25.55万 - 项目类别:
Development of a vaccine to prevent Pneumocystis pneumonia
开发预防肺孢子虫肺炎的疫苗
- 批准号:
9906567 - 财政年份:2020
- 资助金额:
$ 25.55万 - 项目类别:
Pathogenesis of spontaneous pneumocystis pneumonia in Caspase8 and Ripk3 double deficient mice
Caspase8和Ripk3双缺陷小鼠自发性肺孢子虫肺炎的发病机制
- 批准号:
19K17650 - 财政年份:2019
- 资助金额:
$ 25.55万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Therapeutic antibodies to treat Pneumocystis pneumonia in a nonhuman primate model of HIV infection
在 HIV 感染的非人灵长类动物模型中治疗肺孢子虫肺炎的治疗性抗体
- 批准号:
10001636 - 财政年份:2018
- 资助金额:
$ 25.55万 - 项目类别:
Therapeutic antibodies to treat Pneumocystis pneumonia in a nonhuman primate model of HIV infection
在 HIV 感染的非人灵长类动物模型中治疗肺孢子虫肺炎的治疗性抗体
- 批准号:
9624861 - 财政年份:2018
- 资助金额:
$ 25.55万 - 项目类别:
Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia
维生素 D 作为肺孢子菌肺炎的补充疗法
- 批准号:
9063354 - 财政年份:2016
- 资助金额:
$ 25.55万 - 项目类别:
Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia
维生素 D 作为肺孢子虫肺炎的补充疗法
- 批准号:
9238656 - 财政年份:2016
- 资助金额:
$ 25.55万 - 项目类别:
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia
改进肺孢子虫肺炎的治疗和诊断
- 批准号:
10521311 - 财政年份:2016
- 资助金额:
$ 25.55万 - 项目类别:
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia
改进肺孢子虫肺炎的治疗和诊断
- 批准号:
9210593 - 财政年份:2016
- 资助金额:
$ 25.55万 - 项目类别: